IRIS
MADEDDU, Giordano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.556
AS - Asia 7.754
EU - Europa 6.214
SA - Sud America 4.496
AF - Africa 317
Continente sconosciuto - Info sul continente non disponibili 30
OC - Oceania 27
AN - Antartide 1
Totale 36.395
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.234
BR - Brasile 4.029
SG - Singapore 3.460
IT - Italia 2.537
CN - Cina 1.817
UA - Ucraina 1.028
DE - Germania 700
HK - Hong Kong 655
VN - Vietnam 653
FR - Francia 452
FI - Finlandia 297
GB - Regno Unito 265
SE - Svezia 203
AR - Argentina 165
IN - India 153
CA - Canada 134
RU - Federazione Russa 133
BD - Bangladesh 127
TR - Turchia 127
IQ - Iraq 122
NL - Olanda 122
MX - Messico 108
ZA - Sudafrica 88
EC - Ecuador 85
PK - Pakistan 73
PL - Polonia 69
UZ - Uzbekistan 69
MA - Marocco 67
JP - Giappone 65
ES - Italia 60
CZ - Repubblica Ceca 59
VE - Venezuela 56
CO - Colombia 48
RO - Romania 45
NP - Nepal 43
BE - Belgio 41
TN - Tunisia 40
AE - Emirati Arabi Uniti 39
ID - Indonesia 39
KR - Corea 38
PY - Paraguay 34
KE - Kenya 32
AT - Austria 31
JO - Giordania 28
SA - Arabia Saudita 28
AU - Australia 26
AZ - Azerbaigian 26
UY - Uruguay 23
CL - Cile 22
IE - Irlanda 22
KZ - Kazakistan 22
PE - Perù 22
RS - Serbia 22
IL - Israele 21
LT - Lituania 20
KG - Kirghizistan 19
PH - Filippine 17
CH - Svizzera 16
DO - Repubblica Dominicana 16
AL - Albania 15
DZ - Algeria 15
EG - Egitto 15
JM - Giamaica 15
MY - Malesia 15
OM - Oman 15
PS - Palestinian Territory 15
SN - Senegal 15
EU - Europa 14
IR - Iran 14
BG - Bulgaria 13
LB - Libano 13
PA - Panama 13
CR - Costa Rica 12
XK - ???statistics.table.value.countryCode.XK??? 10
HU - Ungheria 9
AM - Armenia 8
BO - Bolivia 8
BY - Bielorussia 8
MD - Moldavia 8
ET - Etiopia 7
GR - Grecia 6
HN - Honduras 6
MK - Macedonia 6
NG - Nigeria 6
PT - Portogallo 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BN - Brunei Darussalam 5
LU - Lussemburgo 5
QA - Qatar 5
SK - Slovacchia (Repubblica Slovacca) 5
AO - Angola 4
CI - Costa d'Avorio 4
LY - Libia 4
NI - Nicaragua 4
GA - Gabon 3
GT - Guatemala 3
KW - Kuwait 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
Totale 36.338
Salva come PNG Salva come JPEG
Città #
Dallas 9.376
Singapore 1.964
Chandler 1.265
San Jose 1.087
Hong Kong 648
Ashburn 617
Jacksonville 579
Beijing 443
Princeton 396
New York 319
São Paulo 263
Rome 244
Lauterbourg 241
Ho Chi Minh City 212
Munich 198
Nanjing 195
Dearborn 190
Los Angeles 179
Hanoi 163
Milan 163
Wilmington 155
Shanghai 153
Sassari 152
Rio de Janeiro 130
Helsinki 128
Boardman 122
Santa Clara 117
Belo Horizonte 114
Ann Arbor 106
Council Bluffs 91
Columbus 90
Nanchang 82
The Dalles 81
Brasília 77
Curitiba 71
Shenyang 70
Naples 66
Campinas 59
Tashkent 59
Tianjin 58
Tokyo 58
Brno 56
Orem 56
Porto Alegre 56
Warsaw 55
Frankfurt am Main 53
Cagliari 51
Florence 49
Woodbridge 47
Denver 45
Montreal 45
San Francisco 45
Changsha 43
Hebei 43
Baghdad 42
Johannesburg 42
London 41
Brooklyn 40
Brussels 40
Nuremberg 40
Salvador 40
Toronto 40
Fortaleza 39
Chennai 37
Guarulhos 37
Buffalo 36
Atlanta 35
Guayaquil 35
Jinan 35
Palermo 34
Seoul 34
Manchester 32
Poplar 32
São José dos Campos 32
Goiânia 31
Phoenix 31
Zhengzhou 31
Da Nang 30
Dhaka 30
Guangzhou 30
São Bernardo do Campo 30
Turin 30
Turku 30
Chicago 29
Houston 29
Nairobi 28
Amsterdam 27
Haiphong 27
Istanbul 27
Jiaxing 27
Mexico City 27
Santo André 27
Sorocaba 27
Amman 26
Lahore 26
Ningbo 26
Recife 26
Ribeirão Preto 26
Norwalk 25
Stockholm 25
Totale 22.896
Salva come PNG Salva come JPEG
Nome #
CASE REPORT: MIOCARDITE ACUTA DA CITOMEGALOVIRUS IN GIOVANE PAZIENTE IMMUNOCOMPETENTE 1.926
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 837
Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives 652
All-cause and Cause-specific Mortality in People With HIV in Italy in 1997–2022: Data From the Icona Cohort 644
Tuberculosis-Induced Immune-Mediated Necrotizing Myopathy: A Challenging Case Scenario in a Non-Endemic Country 570
CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation 534
Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections– results from a retrospective multicentre study 529
Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study 429
PARVOVIRUS B19 E POLIMIALGIA REUMATICA: THE BUTTERFLY EFFECT 336
Assessing the Accuracy, Completeness and Safety of ChatGPT-4o Responses on Pressure Injuries in Infants: Clinical Applications and Future Implications 279
Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with multiple sclerosis? 278
Differences in HCV Seroprevalence, Clinical Features, and Treatment Outcomes between Female and Male Incarcerated Population: Results from a Matched Cohort Study 276
Clinical use of dalbavancin in the Italian SUSANA cohort (SUrveillance of SAfety and outcome of New Antibiotics) 265
How Little Do We Know about HIV and STIs Prevention? Results from a Web-Based Survey among the General Population 263
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort 260
Efficacy and safety of B/F/TAF in naïve people with HIV: real life data from the SHiNeSHiC research group 252
Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options 249
Fluoroquinolones and Biofilm: A Narrative Review 235
Efficacy and tolerability of antiretroviral therapy: focus on people with HIV or on PrEP 226
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV 218
Enzyme biosensors for biomedical applications: Strategies for safeguarding analytical performances in biological fluids 218
Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with multiple sclerosis? 212
99mTc-tetrofosmin SPECT in solitary pulmonary nodule evaluation 211
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 210
Activation of endogenous retroviruses of the HERV-W family by Epstein Barr virus in vitro and in vivo: a dual virus model as the missing link with multiple sclerosis 206
A case of vasculitis-like skin eruption associated with COVID-19 204
Underserved populations and bacterial and protozoal sexually transmitted infections: a lost health-care opportunity 197
The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients 191
Analisi delle Dual Therapy nei pazienti con HIV: Aspetti farmacoeconomici-epidemiologici e clinici 190
Ebola virus disease: Case management in the Institute of Infectious Diseases, University Hospital of Sassari, Sardinia, Italy. 188
Active Case Finding for Communicable Diseases in Prison Settings: Increasing Testing Coverage and Uptake Among the Prison Population in the European Union/European Economic Area 186
Epidemiology, Clinical Aspects, Laboratory Diagnosis and Treatment of Rickettsial Diseases in the Mediterranean Area During COVID-19 Pandemic: A Review of the Literature 181
A longitudinal Study on body compositionin HIV –infected patients receiving HAART. 181
Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases 174
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. 173
HEPATOCELLULAR CARCINOMA DEVELOPMENT IN A PATIENT WITH HCV INFECTION AFTER ERADICATION WITH DIRECT-ACTING ANTIVIRAL AGENTS 172
Mucocutaneous leishmniasis as presentation of HIV infection in Sardinia, insular Italy 171
Acute respiratory distress syndrome due to influenza virus A/H1N1v in a patient with HIV/HCV co-infection 169
Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study 168
Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era 167
Does Angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience 166
Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study 165
Correlations between IL-6 serum level and olfactory dysfunction severity in COVID-19 patients: a preliminary study 164
A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA 162
Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy 159
The burden of HIV-Associated neurocognitive disorder (HAND) in post-HAART era: Amultidisciplinary review of the literature 159
The additional role of 18F-FDG PET/CT in prosthetic valve endocarditis 158
Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials 157
Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study 156
The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients 155
Adverse skin reactions in course of combined antiretroviral therapy 155
Assessing ChatGPT’s Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity 151
Correlations Between Olfactory Psychophysical Scores and SARS-CoV-2 Viral Load in COVID-19 Patients 151
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B 149
Natalizumab therapy modulates miR-155, miR-26a and proinflammatory cytokine expression in MS patients 149
Trends in the European HIV/AIDS epidemic: a perspective from Italy 149
Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy 148
Immune response induced by Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides in current and past infectious mononucleosis: a risk for multiple sclerosis? 148
Meningite linfomatosa in un paziente con linfoma plasmoblastico del cavo orale HIV-relato: ruolo della citarabina liposomiale. 146
Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study. 146
Mood Reactive Disorders among COVID-19 Inpatients: Experience from a Monocentric Cohort 143
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project 142
Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors 141
Cytological and histological diagnosis of lung cancer in Sardinia and Italy in the 1990s 141
Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients 141
Chronic viral hepatitis in the italian prison setting: Prevalence, outcomes, literature needs and perspectives 140
Body composition change in hiv-infected patients treated with HAART: a longitudinal DEXA study. 140
Editorial - Non AIDS-defining malignancies: a new epidemic in HIV-infected population for the upcoming decades? 138
Pneumococcal pneumonia: clinical features, diagnosis and management in HIV-infected and HIV non infected patients 138
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 137
DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy 137
Bacterial community-acquired pneumonia in HIV-infected patients 137
Body composition evaluation by DEXA in the follow up of HIV patients treted with HAART. 137
Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era? 137
Assessing ChatGPT’s theoretical knowledge and prescriptive accuracy in bacterial infections: a comparative study with infectious diseases residents and specialists 136
Arboviral infections in Egyptian and Sardinian children and adults with aseptic meningitis and meningo-encephalitis 135
QuantiFERON TB Gold: a new method for latent tuberculosis infection 135
Kidney disease in HIV-infected patients. 134
Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases 134
Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study 134
Proteomic characterization of hepatitis C eradication: enzyme switch in the healing liver. 133
Utilizzo di EVG/COBI/FTC/TDF in una paziente con viremia elevata e cirrosi HCV-correlata 133
Hepatic echinococcosis: clinical and therapeutic aspects. 133
Body fat changes and mitochondrial alterations during HBV treatment: A warning for long term administration. 132
Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression 131
Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy 130
Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study 129
HIV Infection Indicator Disease-Based Active Case Finding in a University Hospital: Results from the SHOT Project 128
Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience 128
Tuberculosis Screening before Anti–Hepatitis C Virus Therapy in Prisons 128
Circulation of SARS-CoV-2 Among Asylum Seekers: A Real-Life Experience to Address Health Equity in Piacenza, Italy 127
Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report 127
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. 127
Neurocognitive performance and cardiovascular risk in a cohort of HIV-infected patients 127
Vaccinations in prison settings: A systematic review to assess the situation in EU/EEA countries and in other high income countries 126
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 125
Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort 125
CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy. 123
Systemic inflammatory markers and psychophysical olfactory scores in coronavirus disease 2019 patients: is there any correlation? 123
Infectious diseases screening approach among refugees: Results from a single-center study 123
Totale 21.435
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.828
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.828
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021336 0 0 0 0 0 0 0 0 0 224 76 36
2021/20221.109 130 29 26 26 26 32 40 63 83 72 143 439
2022/20232.522 239 209 68 414 208 404 37 274 402 47 130 90
2023/20241.209 139 72 56 40 293 114 35 79 17 48 101 215
2024/20259.092 150 144 492 308 492 405 674 1.560 2.882 1.231 517 237
2025/202618.331 655 3.112 7.385 1.796 1.431 625 1.840 371 580 536 0 0
Totale 36.952